Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 7, 2015, Pages 3800-3807

  Alsultan, Abdullah ^a   An, Guohua ^b   Peloquin, Charles A ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; TUBERCULOSTATIC AGENT;

ACCURACY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BRAZILIAN; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; TUBERCULOSIS; ADOLESCENT; BIOLOGICAL MODEL; BRAZIL; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; MONTE CARLO METHOD; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; BRAZIL; HUMANS; LEVOFLOXACIN; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MODELS, BIOLOGICAL; MONTE CARLO METHOD; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84935912378     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00341-15     Document Type: Article

References (47)

1. World Health Organization. 2014. Global tuberculosis report. World Health Organization, Geneva, Switzerland. http://www.who.int/tb/publications/global-report.
2. Anonymous. 1986. Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council. Am Rev Respir Dis 133:779-783.
3. Anonymous. 1981. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 months. Tubercle 62:95-102. http://dx.doi.org/10.1016/0041-3879(81)90016-7.
4. Centers for Disease Control and Prevention. 2013. Tuberculosis in the United States. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/tb/statistics/surv/surv2013/default.htm.
5. World Health Organization. 2011. How many TB cases have been successfully treated? World Health Organization, Geneva, Switzerland. http://www.who.int/gho/tb/epidemic/treatment/en/.
6. Ji B, Lounis N, Truffot-Pernot C, Grosset J. 1995. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 39:1341-1344. http://dx.doi.org/10.1128/AAC.39.6.1341.
7. Perlman DC, El Sadr WM, Heifets LB, Nelson ET, Matts JP, Chirgwin K, Salomon N, Telzak EE, Klein O, Kreiswirth BN, Musser JM, Hafner R. 1997. Susceptibility to levofloxacin of Myocobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. Community Programs for Clinical Research on AIDS 019 and the AIDS Clinical Trials Group 222 Protocol Team. AIDS 11:1473-1478.
8. Yew WW, Chan CK, Leung CC, Chau CH, Tam CM, Wong PC, Lee J. 2003. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest 124:1476-1481. http://dx.doi.org/10.1378/chest.124.4.1476.
9. Schentag JJ, Meagher AK, Forrest A. 2003. Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 1: in vitro and animal models. Ann Pharmacother 37:1287-1298. http://dx.doi.org/10.1345/aph.1C199.
10. Schentag JJ, Meagher AK, Forrest A. 2003. Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 2: human trials. Ann Pharmacother 37:1478-1488. http://dx.doi.org/10.1345/aph.1C419.
11. Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharath S, Balasubramanian V. 2007. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother 51:576-582. http://dx.doi.org/10.1128/AAC.00414-06.
12. Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL. 2004. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 190:1642-1651. http://dx.doi.org/10.1086/424849.
13. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37:1073-1081. http://dx.doi.org/10.1128/AAC.37.5.1073.
14. Heysell SK, Moore JL, Keller SJ, Houpt ER. 2010. Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. Emerg Infect Dis 16:1546-1553. http://dx.doi.org/10.3201/eid1610.100374.
15. Heysell SK, Moore JL, Staley D, Dodge D, Houpt ER. 2013. Early therapeutic drug monitoring for isoniazid and rifampin among diabetics with newly diagnosed tuberculosis in Virginia, USA. Tuberc Res Treat 2013:129723. http://dx.doi.org/10.1155/2013/129723.
16. Alsultan A, Peloquin CA. 2014. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs 74:839-854. http://dx.doi.org/10.1007/s40265-014-0222-8.
17. Van Tongeren L, Nolan S, Cook VJ, FitzGerald JM, Johnston JC. 2013. Therapeutic drug monitoring in the treatment of tuberculosis: a retrospective analysis. Int J Tuberc Lung Dis 17:221-224. http://dx.doi.org/10.5588/ijtld.12.0279.
18. Magis-Escurra C, van den Boogaard J, Ijdema D, Boeree M, Aarnoutse R. 2012. Therapeutic drug monitoring in the treatment of tuberculosis patients. Pulm Pharmacol Ther 25:83-86. http://dx.doi.org/10.1016/j.pupt.2011.12.001.
19. Babalik A, Mannix S, Francis D, Menzies D. 2011. Therapeutic drug monitoring in the treatment of active tuberculosis. Can Respir J 18:225-229.
20. Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. 2013. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 208:1464-1473. http://dx.doi.org/10.1093/infdis/jit352.
21. Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewell PC, Wells CD, Reingold AL, Kenyon TA, Moeti TL, Tappero JW. 2009. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis 48:1685-1694. http://dx.doi.org/10.1086/599040.
22. Weiner M, Benator D, Burman W, Peloquin CA, Khan A, Vernon A, Jones B, Silva-Trigo C, Zhao Z, Hodge T. 2005. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 40:1481-1491. http://dx.doi.org/10.1086/429321.
23. Burhan E, Ruesen C, Ruslami R, Ginanjar A, Mangunnegoro H, Ascobat P, Donders R, van Crevel R, Aarnoutse R. 2013. Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients. Antimicrob Agents Chemother 57:3614-3619. http://dx.doi.org/10.1128/AAC.02468-12.
24. Peloquin CA, Hadad DJ, Molino LP, Palaci M, Boom WH, Dietze R, Johnson JL. 2008. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 52:852-857. http://dx.doi.org/10.1128/AAC.01036-07.
25. Magis-Escurra C, Later-Nijland HM, Alffenaar JW, Broeders J, Burger DM, van Crevel R, Boeree MJ, Donders AR, van Altena R, van der Werf TS, Aarnoutse RE. 2014. Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin. Int J Antimicrob Agents 44:229-234. http://dx.doi.org/10.1016/j.ijantimicag.2014.04.019.
26. Sprague DA, Ensom MH. 2009. Limited-sampling strategies for anti-infective agents: systematic review. Can J Hosp Pharm 62:392-401. http://dx.doi.org/10.4212/cjhp.v62i5.827.
27. Lavielle M, Mentre F. 2007. Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software. J Pharmacokinet Pharmacodyn 34:229-249. http://dx.doi.org/10.1007/s10928-006-9043-z.
28. Zhu M, Starke JR, Burman WJ, Steiner P, Stambaugh JJ, Ashkin D, Bulpitt AE, Berning SE, Peloquin CA. 2002. Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis. Pharmacotherapy 22:686-695. http://dx.doi.org/10.1592/phco.22.9.686.34067.
29. Alsultan A, Dooley K, Weiner M, Whitworth W, Mac Kenzie WR, Peloquin C. 2013. Population pharmacokinetics of pyrazinamide in patients with tuberculosis, abstr M-040. In Abstr Am Conf Pharmacometrics.
30. Sheiner LB, Beal SL. 1981. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503-512. http://dx.doi.org/10.1007/BF01060893.
31. R Core Team. 2014. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
32. Jayaram R, Shandil RK, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharath S, Kantharaj E, Balasubramanian V. 2004. Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 48:2951-2957. http://dx.doi.org/10.1128/AAC.48.8.2951-2957.2004.
33. Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharat S, Shandil RK, Kantharaj E, Balasubramanian V. 2003. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 47:2118-2124. http://dx.doi.org/10.1128/AAC.47.7.2118-2124.2003.
34. Akkerman OW, van Altena R, Bolhuis MS, van der Werf TS, Alffenaar JW. 2014. Strategy to limit sampling of antituberculosis drugs instead of determining concentrations at two hours postingestion in relation to treatment response, p 628, Antimicrob Agents Chemother 58:628. http://dx.doi.org/10.1128/AAC.01535-13.
35. Pranger AD, Kosterink JG, van Altena R, Aarnoutse RE, van der Werf TS, Uges DR, Alffenaar JW. 2011. Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis. Ther Drug Monit 33:350-354. http://dx.doi.org/10.1097/FTD.0b013e31821b793c.
36. Alffenaar JW, Kosterink JG, van Altena R, van der Werf TS, Uges DR, Proost JH. 2010. Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Ther Drug Monit 32:97-101. http://dx.doi.org/10.1097/FTD.0b013e3181cc6d6f.
37. Tanigawara Y, Nomura H, Kagimoto N, Okumura K, Hori R. 1995. Premarketing population pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseases. Biol Pharm Bull 18:315-320. http://dx.doi.org/10.1248/bpb.18.315.
38. Zhang J, Xu JF, Liu YB, Xiao ZK, Huang JA, Si B, Sun SH, Xia QM, Wu XJ, Cao GY, Shi YG, Zhang YY. 2009. Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China. J Infect Chemother 15:293-300. http://dx.doi.org/10.1007/s10156-009-0714-8.
39. Ginsburg AS, Woolwine SC, Hooper N, Benjamin WH, Jr, Bishai WR, Dorman SE, Sterling TR. 2003. The rapid development of fluoroquinolone resistance in M. tuberculosis. N Engl J Med 349:1977-1978. http://dx.doi.org/10.1056/NEJM200311133492023.
40. Ginsburg AS, Grosset JH, Bishai WR. 2003. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 3:432-442. http://dx.doi.org/10.1016/S1473-3099(03)00671-6.
41. Tam VH, Louie A, Fritsche TR, Deziel M, Liu W, Brown DL, Deshpande L, Leary R, Jones RN, Drusano GL. 2007. Impact of drugexposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial. J Infect Dis 195:1818-1827. http://dx.doi.org/10.1086/518003.
42. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S, PneumA Trial Group. 2003. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 290:2588-2598. http://dx.doi.org/10.1001/jama.290.19.2588.
43. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. 2000. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 162:505-511.
44. D'Agata EM, Magal P, Olivier D, Ruan S, Webb GF. 2007. Modeling antibiotic resistance in hospitals: the impact of minimizing treatment duration. J Theor Biol 249:487-499. http://dx.doi.org/10.1016/j.jtbi.2007.08.011.
45. Drusano GL, Sgambati N, Eichas A, Brown D, Kulawy R, Louie A. 2011. Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system. mBio 2:e00108-11. http://dx.doi.org/10.1128/mBio.00108-11.
46. Cegielski JP, Dalton T, Yagui M, Wattanaamornkiet W, Volchenkov GV, Via LE, Van Der Walt M, Tupasi T, Smith SE, Odendaal R, Leimane V, Kvasnovsky C, Kuznetsova T, Kurbatova E, Kummik T, Kuksa L, Kliiman K, Kiryanova EV, Kim H, Kim CK, Kazennyy BY, Jou R, Huang WL, Ershova J, Erokhin VV, Diem L, Contreras C, Cho SN, Chernousova LN, Chen MP, Caoili JC, Bayona J, Akksilp S, Global Preserving Effective TB Treatment Study (PETTS) Investigators. 2014. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis 59:1049-1063. http://dx.doi.org/10.1093/cid/ciu572.
47. Alffenaar JW, Gumbo T, Aarnoutse RE. 2015. Acquired drug resistance: we can do more than we think! Clin Infect Dis 60:969-970. http://dx.doi.org/10.1093/cid/ciu1146.